國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG)
1.1.0 - Release1.1.0 Taiwan, Province of China flag

This page is part of the 國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG) (v1.1.0: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: SSF2 白血病-白血病分子生物學檢查的評估代碼系統 - TTL Representation

Active as of 2024-08-01

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://hl7.org/fhir/CodeSystem/ssf-2-leukemia-codesystem-cs> a fhir:CodeSystem ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:Resource.id [ fhir:value "ssf-2-leukemia-codesystem-cs"] ;
  fhir:Resource.language [ fhir:value "zh-TW"] ;
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ] ;
     fhir:Narrative.div "<div xml:lang=\"zh-TW\" xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"zh-TW\"><p class=\"res-header-id\"><b>Generated Narrative: 代码系统 ssf-2-leukemia-codesystem-cs</b></p><a name=\"ssf-2-leukemia-codesystem-cs\"> </a><a name=\"hcssf-2-leukemia-codesystem-cs\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: zh-TW</p></div><p>This case-sensitive code system <code>https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">000<a name=\"ssf-2-leukemia-codesystem-cs-000\"> </a></td><td>正常</td></tr><tr><td style=\"white-space:nowrap\">001<a name=\"ssf-2-leukemia-codesystem-cs-001\"> </a></td><td>AML with RUNX1-RUNX1T1</td></tr><tr><td style=\"white-space:nowrap\">002<a name=\"ssf-2-leukemia-codesystem-cs-002\"> </a></td><td>AML with CBFB-MYH11</td></tr><tr><td style=\"white-space:nowrap\">003<a name=\"ssf-2-leukemia-codesystem-cs-003\"> </a></td><td>Acute promyelocytic leukemia with PML-RARA</td></tr><tr><td style=\"white-space:nowrap\">004<a name=\"ssf-2-leukemia-codesystem-cs-004\"> </a></td><td>AML with KMT2A-MLLT3</td></tr><tr><td style=\"white-space:nowrap\">005<a name=\"ssf-2-leukemia-codesystem-cs-005\"> </a></td><td>AML with DEK-NUP214</td></tr><tr><td style=\"white-space:nowrap\">006<a name=\"ssf-2-leukemia-codesystem-cs-006\"> </a></td><td>AML with GATA2, MECOM</td></tr><tr><td style=\"white-space:nowrap\">007<a name=\"ssf-2-leukemia-codesystem-cs-007\"> </a></td><td>AML(megakaryoblastic) with RBM15-MKL1</td></tr><tr><td style=\"white-space:nowrap\">008<a name=\"ssf-2-leukemia-codesystem-cs-008\"> </a></td><td>AML with mutated NPM1</td></tr><tr><td style=\"white-space:nowrap\">009<a name=\"ssf-2-leukemia-codesystem-cs-009\"> </a></td><td>AML with biallelic mutation of CEBPA</td></tr><tr><td style=\"white-space:nowrap\">010<a name=\"ssf-2-leukemia-codesystem-cs-010\"> </a></td><td>AML with mutated FLT3/ITD</td></tr><tr><td style=\"white-space:nowrap\">011<a name=\"ssf-2-leukemia-codesystem-cs-011\"> </a></td><td>AML with mutated FLT3/TKD</td></tr><tr><td style=\"white-space:nowrap\">012<a name=\"ssf-2-leukemia-codesystem-cs-012\"> </a></td><td>AML with MLL-PTD (partial tandem duplication)</td></tr><tr><td style=\"white-space:nowrap\">013<a name=\"ssf-2-leukemia-codesystem-cs-013\"> </a></td><td>AML with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">021<a name=\"ssf-2-leukemia-codesystem-cs-021\"> </a></td><td>B lymphoblastic leukemia/lymphoma with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">022<a name=\"ssf-2-leukemia-codesystem-cs-022\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">023<a name=\"ssf-2-leukemia-codesystem-cs-023\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)</td></tr><tr><td style=\"white-space:nowrap\">024<a name=\"ssf-2-leukemia-codesystem-cs-024\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with IGH/IL3</td></tr><tr><td style=\"white-space:nowrap\">025<a name=\"ssf-2-leukemia-codesystem-cs-025\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)</td></tr><tr><td style=\"white-space:nowrap\">041<a name=\"ssf-2-leukemia-codesystem-cs-041\"> </a></td><td>Mixed phenotype acute leukemia with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">042<a name=\"ssf-2-leukemia-codesystem-cs-042\"> </a></td><td>Mixed-phenotype acute leukemia with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">051<a name=\"ssf-2-leukemia-codesystem-cs-051\"> </a></td><td>Chronic myelogenous leukemia BCR-ABL1 positive</td></tr><tr><td style=\"white-space:nowrap\">052<a name=\"ssf-2-leukemia-codesystem-cs-052\"> </a></td><td>JAK2 V617F mutation</td></tr><tr><td style=\"white-space:nowrap\">053<a name=\"ssf-2-leukemia-codesystem-cs-053\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRA rearrangement</td></tr><tr><td style=\"white-space:nowrap\">054<a name=\"ssf-2-leukemia-codesystem-cs-054\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRB rearrangement</td></tr><tr><td style=\"white-space:nowrap\">055<a name=\"ssf-2-leukemia-codesystem-cs-055\"> </a></td><td>Myeloid and lymphoid neoplasms with FGFR1 rearrangement</td></tr><tr><td style=\"white-space:nowrap\">090<a name=\"ssf-2-leukemia-codesystem-cs-090\"> </a></td><td>(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">091<a name=\"ssf-2-leukemia-codesystem-cs-091\"> </a></td><td>同時有兩種(含)以上上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">092<a name=\"ssf-2-leukemia-codesystem-cs-092\"> </a></td><td>同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">8XX<a name=\"ssf-2-leukemia-codesystem-cs-8XX\"> </a></td><td>Molecular study after chemotherapy or immunotherapy or target therapy</td></tr><tr><td style=\"white-space:nowrap\">988<a name=\"ssf-2-leukemia-codesystem-cs-988\"> </a></td><td>不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)</td></tr><tr><td style=\"white-space:nowrap\">998<a name=\"ssf-2-leukemia-codesystem-cs-998\"> </a></td><td>有執行分子生物學檢查，但結果無法判斷</td></tr><tr><td style=\"white-space:nowrap\">999<a name=\"ssf-2-leukemia-codesystem-cs-999\"> </a></td><td>(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查</td></tr></table></div>"
  ] ;
  fhir:CodeSystem.url [ fhir:value "https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs"] ;
  fhir:CodeSystem.version [ fhir:value "1.1.0"] ;
  fhir:CodeSystem.name [ fhir:value "SSF2leukemiaCS"] ;
  fhir:CodeSystem.title [ fhir:value "SSF2 白血病-白血病分子生物學檢查的評估代碼系統"] ;
  fhir:CodeSystem.status [ fhir:value "active"] ;
  fhir:CodeSystem.experimental [ fhir:value "false"^^xsd:boolean] ;
  fhir:CodeSystem.date [ fhir:value "2024-08-01T15:33:47+08:00"^^xsd:dateTime] ;
  fhir:CodeSystem.publisher [ fhir:value "國家衛生研究院"] ;
  fhir:CodeSystem.contact [
     fhir:index 0 ;
     fhir:ContactDetail.name [ fhir:value "國家衛生研究院" ] ;
     fhir:ContactDetail.telecom [
       fhir:index 0 ;
       fhir:ContactPoint.system [ fhir:value "url" ] ;
       fhir:ContactPoint.value [ fhir:value "https://ghd.tw/" ]
     ]
  ] ;
  fhir:CodeSystem.description [ fhir:value "Assessment of molecular studies in leukemia Code System"] ;
  fhir:CodeSystem.jurisdiction [
     fhir:index 0 ;
     fhir:CodeableConcept.coding [
       fhir:index 0 ;
       fhir:Coding.system [ fhir:value "urn:iso:std:iso:3166" ] ;
       fhir:Coding.code [ fhir:value "TW" ]
     ]
  ] ;
  fhir:CodeSystem.caseSensitive [ fhir:value "true"^^xsd:boolean] ;
  fhir:CodeSystem.content [ fhir:value "complete"] ;
  fhir:CodeSystem.count [ fhir:value "33"^^xsd:nonNegativeInteger] ;
  fhir:CodeSystem.concept [
     fhir:index 0 ;
     fhir:CodeSystem.concept.code [ fhir:value "000" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "正常" ]
  ], [
     fhir:index 1 ;
     fhir:CodeSystem.concept.code [ fhir:value "001" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with RUNX1-RUNX1T1" ]
  ], [
     fhir:index 2 ;
     fhir:CodeSystem.concept.code [ fhir:value "002" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with CBFB-MYH11" ]
  ], [
     fhir:index 3 ;
     fhir:CodeSystem.concept.code [ fhir:value "003" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Acute promyelocytic leukemia with PML-RARA" ]
  ], [
     fhir:index 4 ;
     fhir:CodeSystem.concept.code [ fhir:value "004" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with KMT2A-MLLT3" ]
  ], [
     fhir:index 5 ;
     fhir:CodeSystem.concept.code [ fhir:value "005" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with DEK-NUP214" ]
  ], [
     fhir:index 6 ;
     fhir:CodeSystem.concept.code [ fhir:value "006" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with GATA2, MECOM" ]
  ], [
     fhir:index 7 ;
     fhir:CodeSystem.concept.code [ fhir:value "007" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML(megakaryoblastic) with RBM15-MKL1" ]
  ], [
     fhir:index 8 ;
     fhir:CodeSystem.concept.code [ fhir:value "008" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with mutated NPM1" ]
  ], [
     fhir:index 9 ;
     fhir:CodeSystem.concept.code [ fhir:value "009" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with biallelic mutation of CEBPA" ]
  ], [
     fhir:index 10 ;
     fhir:CodeSystem.concept.code [ fhir:value "010" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with mutated FLT3/ITD" ]
  ], [
     fhir:index 11 ;
     fhir:CodeSystem.concept.code [ fhir:value "011" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with mutated FLT3/TKD" ]
  ], [
     fhir:index 12 ;
     fhir:CodeSystem.concept.code [ fhir:value "012" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with MLL-PTD (partial tandem duplication)" ]
  ], [
     fhir:index 13 ;
     fhir:CodeSystem.concept.code [ fhir:value "013" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "AML with BCR-ABL1" ]
  ], [
     fhir:index 14 ;
     fhir:CodeSystem.concept.code [ fhir:value "021" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "B lymphoblastic leukemia/lymphoma with BCR-ABL1" ]
  ], [
     fhir:index 15 ;
     fhir:CodeSystem.concept.code [ fhir:value "022" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged" ]
  ], [
     fhir:index 16 ;
     fhir:CodeSystem.concept.code [ fhir:value "023" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)" ]
  ], [
     fhir:index 17 ;
     fhir:CodeSystem.concept.code [ fhir:value "024" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "B-lymphoblastic leukemia/lymphoma with IGH/IL3" ]
  ], [
     fhir:index 18 ;
     fhir:CodeSystem.concept.code [ fhir:value "025" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)" ]
  ], [
     fhir:index 19 ;
     fhir:CodeSystem.concept.code [ fhir:value "041" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Mixed phenotype acute leukemia with BCR-ABL1" ]
  ], [
     fhir:index 20 ;
     fhir:CodeSystem.concept.code [ fhir:value "042" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Mixed-phenotype acute leukemia with KMT2A-rearranged" ]
  ], [
     fhir:index 21 ;
     fhir:CodeSystem.concept.code [ fhir:value "051" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Chronic myelogenous leukemia BCR-ABL1 positive" ]
  ], [
     fhir:index 22 ;
     fhir:CodeSystem.concept.code [ fhir:value "052" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "JAK2 V617F mutation" ]
  ], [
     fhir:index 23 ;
     fhir:CodeSystem.concept.code [ fhir:value "053" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Myeloid and lymphoid neoplasms with PDGFRA rearrangement" ]
  ], [
     fhir:index 24 ;
     fhir:CodeSystem.concept.code [ fhir:value "054" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Myeloid and lymphoid neoplasms with PDGFRB rearrangement" ]
  ], [
     fhir:index 25 ;
     fhir:CodeSystem.concept.code [ fhir:value "055" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Myeloid and lymphoid neoplasms with FGFR1 rearrangement" ]
  ], [
     fhir:index 26 ;
     fhir:CodeSystem.concept.code [ fhir:value "090" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常" ]
  ], [
     fhir:index 27 ;
     fhir:CodeSystem.concept.code [ fhir:value "091" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "同時有兩種(含)以上上述之分子檢驗異常" ]
  ], [
     fhir:index 28 ;
     fhir:CodeSystem.concept.code [ fhir:value "092" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常" ]
  ], [
     fhir:index 29 ;
     fhir:CodeSystem.concept.code [ fhir:value "8XX" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "Molecular study after chemotherapy or immunotherapy or target therapy" ]
  ], [
     fhir:index 30 ;
     fhir:CodeSystem.concept.code [ fhir:value "988" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)" ]
  ], [
     fhir:index 31 ;
     fhir:CodeSystem.concept.code [ fhir:value "998" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "有執行分子生物學檢查，但結果無法判斷" ]
  ], [
     fhir:index 32 ;
     fhir:CodeSystem.concept.code [ fhir:value "999" ] ;
     fhir:CodeSystem.concept.display [ fhir:value "(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查" ]
  ] .

# - ontology header ------------------------------------------------------------

<http://hl7.org/fhir/CodeSystem/ssf-2-leukemia-codesystem-cs.ttl> a owl:Ontology ;
  owl:imports fhir:fhir.ttl ;
  owl:versionIRI <http://build.fhir.org/CodeSystem/ssf-2-leukemia-codesystem-cs.ttl> .